EC Paediatrics

Review Article Volume 13 Issue 10 - 2024

Growth Factors, Cell Receptors, Intracellular Kinases, and Transcription Factors Associated with Schizophrenia

AJ Russo1*, Albert Mensah2 and Judith Bowman2

1Visiting Professor, Hartwick College Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA
 2Mensah Research Institute, Warrenville, Il, USA

*Corresponding Author: AJ Russo, Visiting Professor, Hartwick College Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA.
Received: September 13, 2024; Published: September 24, 2024




Schizophrenia is a complex neuropsychiatric disorder characterized by a range of symptoms, including cognitive deficits, hallucinations, and delusions. The pathophysiology of schizophrenia has been linked to growth factors, cell receptors, intracellular kinases, and transcription factors. This paper is a review of these cellular factors which are associated with the etiology of schizophrenia.

 Keywords: Schizophrenia; Growth Factors; Cell Receptors; Intracellular Kinases

  1. Chen D., et al. “Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes”. Psychopharmacology3 (2009): 375-380.
  2. Lee AH., et al. “Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment”. Journal of Clinical Psychopharmacology3 (2011): 334-336.
  3. Angelucci F., et al. “Bdnf in schizophrenia, depression and corresponding animal models”. Molecular Psychiatry4 (2005): 345-352.
  4. Chao H., et al. “Bdnf val66met variant and age of onset in schizophrenia”. American Journal of Medical Genetics Part B Neuropsychiatric Genetics 4 (2008): 505-506.
  5. Neves-Pereira M., et al. “Bdnf gene is a risk factor for schizophrenia in a Scottish population”. Molecular Psychiatry2 (2005): 208-212.
  6. Fumagalli F., et al. “Corticostriatal brain‐derived neurotrophic factor dysregulation in adult rats following prenatal stress”. European Journal of Neuroscience5 (2004): 1348-1354.
  7. Wang L., et al. “The mediating effect of brain-derived neurotrophic factor levels on childhood trauma and psychiatric symptoms in patients with first-episode schizophrenia”. Australian and New Zealand Journal of Psychiatry7 (2022): 828-835.
  8. Green M., et al. “Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis”. Molecular Psychiatry9 (2010): 960-972.
  9. Vinogradov S., et al. “Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?”. Biological Psychiatry6 (2009): 549-553.
  10. Guillin O., et al. “Bdnf controls dopamine d3 receptor expression and triggers behavioural sensitization”. Nature6833 (2001): 86-89.
  11. D’Souza DC., et al. “Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (bdnf) levels in humans”. Psychopharmacology4 (2008): 569-578.
  12. Vakhrusheva J., et al. “Aerobic exercise in people with schizophrenia: neural and neurocognitive benefits”. Current Behavioral Neuroscience Reports2 (2016): 165-175.
  13. Han M and Deng C. “Bdnf as a pharmacogenetic target for antipsychotic treatment of schizophrenia”. Neuroscience Letters 726 (2020): 133870.
  14. Penadés R., et al. “Brain-derived neurotrophic factor as a potential biomarker of cognitive recovery in schizophrenia”. World Journal of Psychiatry4 (2013): 93.
  15. Gu H., et al. “Synthesis and biological evaluation of novel flavanone derivatives as potential antipsychotic agents”. Chemical Biology and Drug Design3 (2016): 353-364.
  16. Pollak TA., et al. “Prevalence of anti-n-methyl-d-aspartate (nmda) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis”. Psychological Medicine12 (2013): 2475-2487.
  17. Watson DJ., et al. “Blockade of dopamine d3 but not d2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment”. The International Journal of Neuropsychopharmacology4 (2011): 471-484.
  18. Sokoloff P., et al. “Direct and indirect interactions of the dopamine d3 receptor with glutamate pathways: implications for the treatment of schizophrenia”. Naunyn-Schmiedeberg's Archives of Pharmacology2 (2012): 107-124.
  19. Tsutsui K., et al. “N-methyl-d-aspartate receptor antibody could be a cause of catatonic symptoms in psychiatric patients: case reports and methods for detection”. Neuropsychiatric Disease and Treatment 13 (2017): 339-345.
  20. Ikemot K. ““d-cell hypothesis” of schizophrenia: possible theory for mesolimbic dopamine hyperactivity”. World Journal of Neuroscience3 (2012): 141-144.
  21. Wang HY., et al. “Mglur5 hypofunction is integral to glutamatergic dysregulation in schizophrenia”. Molecular Psychiatry4 (2020): 750-760.
  22. Nicoletti F., et al. “Targeting mglu receptors for optimization of antipsychotic activity and disease-modifying effect in schizophrenia”. Frontiers in Psychiatry 10 (2019): 49.
  23. Glausier JR and Lewis DA. “Selective pyramidal cell reduction of gabaa receptor α1 subunit messenger rna expression in schizophrenia”. Neuropsychopharmacology10 (2011): 2103-2110.
  24. Beneyto MG., et al. “Lamina-specific alterations in cortical gabaa receptor subunit expression in schizophrenia”. Cerebral Cortex5 (2010): 999-1011.
  25. Gill K and Grace AA. “Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in mam schizophrenia model”. The International Journal of Neuropsychopharmacology10 (2014): 1609-1619.
  26. Joshi D., et al. “Relationship between somatostatin and death receptor expression in the orbital frontal cortex in schizophrenia: a postmortem brain mrna study”. NPJ Schizophrenia1 (2015): 14004.
  27. Jardemark K., et al. “Effects of asenapine on prefrontal n‐methyl‐d‐aspartate receptor‐mediated transmission: involvement of dopamine d1 receptors”. Synapse11 (2010): 870-874.
  28. Rodrigues-Amorím D., et al. “The role of the second extracellular loop of norepinephrine transporter, neurotrophin-3 and tropomyosin receptor kinase c in t cells: a peripheral biomarker in the etiology of schizophrenia”. International Journal of Molecular Sciences16 (2021): 8499.
  29. Arakelyan A., et al. “Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia”. BMC Clinical Pathology1 (2011): 10.
  30. Freyberg Z., et al. “Roles of the akt/gsk-3 and wnt signaling pathways in schizophrenia and antipsychotic drug action”. American Journal of Psychiatry4 (2010): 388-396.
  31. Sutton LP and Rushlow W. “Regulation of akt and wnt signaling by the group ii metabotropic glutamate receptor antagonist ly341495 and agonist ly379268”. Journal of Neurochemistry6 (2011): 973-983.
  32. Wong P., et al. “Pregnenolone sulfate normalizes schizophrenia-like behaviors in dopamine transporter knockout mice through the akt/gsk3β pathway”. Translational Psychiatry3 (2015): e528.
  33. Su P., et al. “Clozapine modulates the glycogen synthase kinase-3 signaling partly via gabab receptors”. Annals of Biological Sciences1 (2017).
  34. Brown CN., et al. “Characterization of six camkiiα variants found in patients with schizophrenia”. iScience10 (2021): 103184.
  35. Rawas RE., et al. “The anti-social brain in schizophrenia: a role of camkii?”. Frontiers in Psychiatry 13 (2022): 868244.
  36. Funk A., et al. “Abnormal activity of the mapk- and camp-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia”. Neuropsychopharmacology4 (2011): 896-905.
  37. McGuire JL., et al. “Abnormalities of signal transduction networks in chronic schizophrenia”. NPJ Schizophrenia1 (2017): 30.
  38. Morris DW., et al. “An inherited duplication at the gene p21 protein-activated kinase 7 (pak7) is a risk factor for psychosis”. Human Molecular Genetics12 (2014): 3316-3326.
  39. Datta D., et al. “Altered expression of cdc42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia”. Biological Psychiatry11 (2015): 775-785.
  40. Banerjee A., et al. “Src kinase as a mediator of convergent molecular abnormalities leading to nmdar hypoactivity in schizophrenia”. Molecular Psychiatry9 (2014): 1091-1100.
  41. Katanuma Y., et al. “Phencyclidine rapidly decreases neuronal mrna of brain-derived neurotrophic factor”. Synapse6 (2014): 257-265.
  42. Balu DT., et al. “Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of nmda receptor hypofunction”. Proceedings of the National Academy of Sciences26 (2013): E2400-E2409.
  43. Wright C., et al. “Potential impact of mir-137 and its targets in schizophrenia”. Frontiers in Genetics 4 (2013): 58.
  44. Agrawal R., et al. “In silico model-driven assessment of the effects of brain-derived neurotrophic factor deficiency on glutamate and gamma-aminobutyric acid: implications for understanding schizophrenia pathophysiology”. Clinical Psychopharmacology and Neuroscience2 (2017): 115-125.
  45. Ruzicka WB., et al. “Single-cell dissection of schizophrenia reveals neurodevelopmental-synaptic axis and transcriptional resilience”. medRxiv (2020).
  46. Xia H., et al. “Building a schizophrenia genetic network: transcription factor 4 regulates genes involved in neuronal development and schizophrenia risk”. Human Molecular Genetics18 (2018): 3246-3256.
  47. Kwon EJ., et al. “Validation of schizophrenia-associated genes csmd1, c10orf26, cacna1c and tcf4 as mir-137 targets”. Molecular Psychiatry1 (2011): 11-12.
  48. Forrest MP., et al. “Knockdown of human tcf4 affects multiple signaling pathways involved in cell survival, epithelial to mesenchymal transition and neuronal differentiation”. PLoS ONE8 (2013): e73169.
  49. Swain S., et al. “A study of nuclear factor-kappa b1 gene polymorphism types in schizophrenia patients and their correlation with disease severity”. Cureus4 (2022): e24401.
  50. Safa A., et al. “Expression of nf-κb associated lncrnas in schizophrenia”. Scientific Reports1 (2020): 18105.
  51. Ohnishi T., et al. “Cooperation of lim domain‐binding 2 (ldb2) with egr in the pathogenesis of schizophrenia”. EMBO Molecular Medicine4 (2021): e12574.
  52. Miller B., et al. “Microrna-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function”. Proceedings of the National Academy of Sciences8 (2012): 3125-3130.
  53. Xia H., et al. “Building a schizophrenia genetic network: transcription factor 4 regulates genes involved in neuronal development and schizophrenia risk”. Human Molecular Genetics18 (2018): 3246-3256.
  54. Wei H., et al. “Detection of circulating mirna levels in schizophrenia”. American Journal of Psychiatry11 (2015): 1141-1147.
  55. Smirnova L., et al. “The difference in serum proteomes in schizophrenia and bipolar disorder”. BMC Genomics7 (2019): 535.
  56. Kurita M., et al. “Hdac2 regulates atypical antipsychotic responses through the modulation of mglu2 promoter activity”. Nature Neuroscience9 (2012): 1245-1254.

AJ Russo., et al. "Growth Factors, Cell Receptors, Intracellular Kinases, and Transcription Factors Associated with Schizophrenia". EC Paediatrics 13.10 (2024): 01-09.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net